

Mariano Severgnini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/853551/publications.pdf>

Version: 2024-02-01

31
papers

1,175
citations

623734

14
h-index

642732

23
g-index

31
all docs

31
docs citations

31
times ranked

2519
citing authors

#	ARTICLE	IF	CITATIONS
1	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. <i>Blood Advances</i> , 2022, 6, 2183-2194.	5.2	12
2	Mass cytometry staining for human bone marrow clinical samples. <i>STAR Protocols</i> , 2022, 3, 101163.	1.2	1
3	Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2022, 10, e003569.		10
4	Simplified mass cytometry protocol for in-plate staining, barcoding, and cryopreservation of human PBMC samples in clinical trials. <i>STAR Protocols</i> , 2022, 3, 101362.	1.2	1
5	Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling. <i>Immunotherapy</i> , 2022, 14, 843-850.	2.0	3
6	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 134-144.	0.8	61
7	Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2209-2221.	4.2	32
8	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2470-2480.	7.0	51
9	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.	1.4	24
10	A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. <i>Cancer Cell</i> , 2021, 39, 380-393.e8.	16.8	27
11	Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2991-3000.	4.2	18
12	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). , 2021, 9, e001504.		72
13	Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. <i>Blood Advances</i> , 2021, 5, 4701-4709.	5.2	12
14	Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. , 2021, 9, e002472.		13
15	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.	12.8	19
16	Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. , 2021, 9, e003318.		7
17	Mechanical Checkpoint Regulates Monocyte Differentiation in Fibrotic Matrix. <i>Blood</i> , 2021, 138, 2539-2539.	1.4	5
18	Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. , 2020, 8, e000678.		78

#	ARTICLE	IF	CITATIONS
19	High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples. STAR Protocols, 2020, 1, 100055.	1.2	19
20	Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells. Journal of Biological Methods, 2020, 7, e131.	0.6	6
21	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. Oncologist, 2019, 24, 1013-1021.	3.7	15
22	Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. Journal of Biological Methods, 2019, 6, e114.	0.6	14
23	Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients. Cell and Tissue Banking, 2018, 19, 783-790.	1.1	17
24	Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. , 2018, 6, 18.		153
25	Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells. Cytotechnology, 2018, 70, 1-11.	1.6	11
26	Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1440930.	4.6	30
27	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer, 2017, 123, 3285-3290.	4.1	170
28	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunology Research, 2017, 5, 17-28.	3.4	130
29	Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. , 2016, 4, 32.		17
30	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. British Journal of Cancer, 2016, 115, 252-260.	6.4	66
31	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunology Research, 2016, 4, 679-687.	3.4	81